This month, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), trade groups representing the biopharmaceutical and biotechnology industries, announced that they are challenging Nevada’s Senate Bill (SB) 539 in district court litigation.
This month, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), trade groups representing the biopharmaceutical and biotechnology industries, announced that they are challenging Nevada’s Senate Bill (SB) 539 in district court litigation.
Passed in June 2017 by constitutional majorities in both the Nevada Assembly and Senate, the bill was signed into law by Governor Brian Sandoval (R). Among other provisions, the law requires drug manufacturers to annually disclose list prices set for insulins, profits made, and discounts provided to pharmacy benefit managers (PBMs). It also requires drug makers to explain insulin price increases that are above the prior year’s inflation rate (or twice the inflation rate of the past 2 years).
Manufacturers could face daily fines if they fail to provide the required data. The bill also permits pharmacists to provide patients with information about lower-priced alternative prescription options.
According to the groups’ complaint, the “unprecedented and unconstitutional Nevada law… interferes with the federal patent and trade-secret laws, deprives manufacturers of their property interest in their trade secrets, and improperly overrides the regulatory choices of every other state.” PhRMA and BIO are seeking a declaration from the court that sections of SB 539 are preempted by federal law, and that they violate the US Constitution. They also seek a preliminary and permanent injunction prohibiting implementation or enforcement of the provisions at issue.
“While the purpose of the Act is to control prices for diabetes drugs, neither the Act nor its legislative history explain how transparency will lower prices apart from impermissibly burdening manufacturers’ lawful exercise of federal patent rights. The Constitution entrusts national economic policy to Congress precisely to avoid such outcomes,” according to the group’s complaint.
Governor Sandoval said that the suit did not come as a surprise to his office, and that the state’s attorney general would “vigorously defend this existing state law which was passed with bipartisan majorities of both houses.”
Nevada’s law is not the only state-based drug pricing initiative to find itself the target of a lawsuit this month; trade group the Association for Accessible Medicines has filed a suit in Maryland, claiming that the state’s House Bill (HB) 631 is unconstitutional.
HB 631, originally slated to take effect next month, would require the Maryland Medical Assistance Program to notify the state’s attorney general of increase in the prices of generic or off-patent treatments, and would authorize the attorney general to both demand drug makers’ records and impose penalties on manufacturers who violate the law.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.